Eton Pharmaceuticals (ETON) Share-based Compensation (2018 - 2025)

Eton Pharmaceuticals has disclosed Share-based Compensation across 8 years of filings, most recently posting $1.1 million for Q4 2025.

• Share-based Compensation for Q4 2025 came in at $1.1 million, up 43.73% year-over-year; the trailing twelve-month figure through Dec 2025 was $5.5 million (up 80.6% YoY), and the FY2025 annual result was $5.5 million, up 74.15% from the prior year.
• Share-based Compensation came in at $1.1 million for Q4 2025 at Eton Pharmaceuticals, up from $1.1 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $2.1 million in Q2 2025 to a low of $673000.0 in Q1 2021.
• The 5-year median for Share-based Compensation is $867500.0 (2021), against an average of $960650.0.
• Across the five-year window, Share-based Compensation plunged 46.31% in 2023 and surged 188.31% in 2025, its largest moves.
• Eton Pharmaceuticals' Share-based Compensation stood at $863000.0 in 2021, then gained by 2.67% to $886000.0 in 2022, then slipped by 15.35% to $750000.0 in 2023, then grew by 4.27% to $782000.0 in 2024, then surged by 43.73% to $1.1 million in 2025.
• The last three Share-based Compensation figures came in at $1.1 million (Q4 2025), $1.1 million (Q3 2025), and $2.1 million (Q2 2025), per Business Quant data.